Improving visual acuity with Pasplanar vitrectomy using PRP for progressive diabetic retinopathy

Published Date: 06 Mar 2023

Diabetic retinopathy is a leading cause of vision loss, with diabetic retinopathy (DDR) representing the most severe form of...

Read Full News

Latest News

New Parameters for Faster Geographic Atrophy Progression Established, with Srinivas Sadda, MD Srinivas Sadda, MD

The pooled sham cohorts of the OAKS and DERBY trials have revealed a series of indicators for faster geographic atrophy lesion growth.

OCU-410 Gene Therapy Preserves Visual Acuity and Slows GA Lesion Progression, with Jay Chhablani, MD Jay Chhablani, MD

Recent phase 1/2 trial data indicate the safety and efficacy of the surgical, subretinal injection in monitoring cellular homeostasis.

Intravitreal UBX1325 Shows Efficacy in Diabetic Retinopathy, DME, with Dante Pieramici, MD Dante J. Pieramici, MD

Results from the BEHOLD and ASPIRE trials indicate the long lasting effects of UBX1325 in improving retinal function and structure.

Q3 2025 Recap: Ophthalmology News and Updates Ryan Livingston

The Q3 recap for ophthalmology spotlights major FDA decisions and major clinical trial updates in a variety of diseases.

Psoriasis Associated with Risk of Age-Related Macular Degeneration Ryan Livingston

Based on 3 propensity-matched control groups, patients with psoriasis can have anywhere from a 40% to 56% higher risk.

Correlation Between Diabetes and Risk of Uveitis Confirmed in Recent Study Ryan Livingston

In addition to type 1 and 2 diabetes, diabetic retinopathy substantially increases the risk of developing and worsening uveitis.

Todays Updates

CAR-T Therapy KYV-101 Achieves Durable Response in Phase 2/3 KYSA-6 Trial of Myasthenia Gravis Marco Meglio

KYV-101 shows promising efficacy in treating generalized myasthenia gravis, offering hope for durable remission through innovative CAR T-cell therapy.

Reimagining Neuroscience Trials: Precision, Partnership, and Progress Marco Meglio, Daniel Mikol, MD, PhD

Daniel Mikol, MD, PhD, vice president of neuroscience development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.

MIL62 Shows Increased Remission and Reduced Relapse Versus Cyclosporine A in MN

MIL62 Shows Increased Remission and Reduced Relapse Versus Cyclosporine A in MN

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

Todays Updates

CAR-T Therapy KYV-101 Achieves Durable Response in Phase 2/3 KYSA-6 Trial of Myasthenia Gravis Marco Meglio

KYV-101 shows promising efficacy in treating generalized myasthenia gravis, offering hope for durable remission through innovative CAR T-cell therapy.

Reimagining Neuroscience Trials: Precision, Partnership, and Progress Marco Meglio, Daniel Mikol, MD, PhD

Daniel Mikol, MD, PhD, vice president of neuroscience development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.

MIL62 Shows Increased Remission and Reduced Relapse Versus Cyclosporine A in MN

MIL62 Shows Increased Remission and Reduced Relapse Versus Cyclosporine A in MN

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

The HCPFive: Top News for Healthcare Providers from the Week of 11/16

Latest News

The pooled sham cohorts of the OAKS and DERBY trials have revealed a series of indicators for faster geographic atrophy lesion growth.

Recent phase 1/2 trial data indicate the safety and efficacy of the surgical, subretinal injection in monitoring cellular homeostasis.

Results from the BEHOLD and ASPIRE trials indicate the long lasting effects of UBX1325 in improving retinal function and structure.

The Q3 recap for ophthalmology spotlights major FDA decisions and major clinical trial updates in a variety of diseases.

Based on 3 propensity-matched control groups, patients with psoriasis can have anywhere from a 40% to 56% higher risk.

In addition to type 1 and 2 diabetes, diabetic retinopathy substantially increases the risk of developing and worsening uveitis.

News All Time

Eye scans reveal clues to aging and heart disease risk, study finds

The tiny blood vessels in your eyes might hold the key to predicting a person's risk of developing heart disease and how fast they're biologically aging, according to researchers at McMaster University and Population Health ...

LASIK armed with 3D eye model provides better vision correction

An advanced form of LASIK (Laser-Assisted In-Situ Keratomileusis) eye surgery that uses a virtual 3D model of a person's eye appears to offer patients better vision, a new study says.

Fancy dress contact lenses can cause infections, ulcers, even blindness—how to keep your eyes safe this Halloween

With Halloween just around the corner, thousands will be shopping for fancy dress contact lenses to go with their costume. The appeal is clear, as their endless colors and shapes allow you to radically change how you look—who ...

Cataract surgery becoming an in-office procedure, experts say

Imagine popping by your eye doctor's office for a quick cataract surgery.

Age-related macular degeneration: Robot delivers ultra-precision injections with rapid setup times

Many surgeons admit that medical robots can now operate with greater precision than human specialists. However, the complex preparation required for robotic surgery still takes far too long. But a new robotic assistant for ...

Risk of eye disease increases during menopause transition

Many symptoms, such as hot flashes and vaginal dryness, are commonly associated with the menopause transition. One of the lesser-known symptoms that worsens in midlife is dry eyes. A new study suggests that postmenopausal ...

Like radar, a brain wave sweeps a cortical region to read out information held in working memory

Imagine you are a security guard in one of those casino heist movies where your ability to recognize an emerging crime will depend on whether you notice a subtle change on one of the many security monitors arrayed on your ...

Transformative eye research expands donor pool for corneal transplant patients

Many eye banks won't accept corneas from donors with diabetes, concerned they might be harder to prepare for transplant surgery or are more likely to fail.

Pickleball popularity surge serves up spike in serious eye injuries

Rutgers New Jersey Medical School-led researchers have identified a striking rise in pickleball-related eye injuries among players visiting emergency departments across the United States. Using two decades of national surveillance ...

Patient wealth is associated with quality of glaucoma care

Patients with newly diagnosed glaucoma who have less wealth or reside in rural communities are less likely to receive standard glaucoma care compared to wealthier patients, according to a recent multi-institutional study ...

Vision therapy reverses concussion-related double and blurred vision, study finds

Nearly half of adolescents and young adults with lingering symptoms of concussion suffer from eye coordination disorders that cause double and blurred vision, headaches and difficulties concentrating.

FDA authorizes Essilor Stellest eyeglass lenses for children with myopia

The U.S. Food and Drug Administration has authorized marketing of the Essilor Stellest eyeglass lenses to correct myopia, with or without astigmatism, and to slow the progression of the disease in children 6 to 12 years old.

mRNA vaccine shows promise for treating age-related macular degeneration

An mRNA vaccine developed by researchers from Japan suppressed abnormal blood vessel growth or neovascularization in the retina of mouse models. Neovascularization is a condition that is caused by age-related macular degeneration ...

Bringing eye images into focus with AI

Researchers at the University of Waterloo have developed a better way to enhance the clarity and detail of eye images used to diagnose disease by teaching artificial intelligence (AI) software the science behind the imaging ...

Polyunsaturated fatty acid therapy reverses age-related vision decline in mice

Changes in vision are often a common sign of aging. But what if we could reverse age-related visual decline? In a new study, UC Irvine researchers explore a possible therapy for addressing "aging" in the eye and for preventing ...

AI at the eyelid: Glasses that track health through your blinks

Penn researchers have developed an AI-powered device that turns ordinary glasses into a smart, energy-efficient health monitor by watching you blink.

Recommended News For You

New Zealand and Australian breast cancer rates among the highest in the world, global study finds

According to the Lancet, having cancer and VTE at the same time increases mortality risk.

Sydney researchers identify new tools to improve cancer diagnosis and treatment.

Adaptive SABR-Used Hypofractionated Chemoradiation Showed Good Results in NSCLC.

Earlier Info on Financial Stress; Obesity and Second Cancers; Carcinogenic Condoms?

Cancer deaths expected to rise to over 18 million in 2050, nearly 75% more than in 2024

Using AI, one can find cancer risk factors.

Recommended Articles For You

Chondroma: What it is and How it Affects Your Health  

Mastering Breast Cancer Care in 2025: Diagnosis, Treatment, Education, and Innovation 

Cancer Trials 2025: Vaccines, Metabolic Targets, and the Microbiome in Oncology 

Future of Chemotherapy: New Advances, Treatments & Survival Rates Transforming Cancer Care 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA Greenlights First Engineered Cell Therapy for a Solid Tumor

2.

New CAR-T Drug Induces Durable Remissions in ALL, Published Data Show

3.

The FDA Approves the New Frontline Aggressive ALL Regimen.

4.

Childhood brain tumors develop early in highly specialized nerve cells, research reveals

5.

Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.

1.

Decoding Granular Cell Tumor: What You Need to Know

2.

Omega-3 Fatty Acids as Molecular Adjuvants Against Chemoresistance in Breast Cancer

3.

Mechanistic Insights into Abraxane, Verzenio, and the Management of Chemotherapy-Induced Tachycardia

4.

Unlocking the Power of Cryoprecipitate: A Comprehensive Guide

5.

Frontiers in Cancer Therapeutics: U.S. Oncology Trials and Drug Discovery Trends

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II

2.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV

3.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

4.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II

5.

Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot